Copyright: ©Author(s) 2026.
World J Gastroenterol. Jul 7, 2026; 32(25): 119434
Published online Jul 7, 2026. doi: 10.3748/wjg.119434
Published online Jul 7, 2026. doi: 10.3748/wjg.119434
Table 4 Summary of treatment-emergent adverse events (per safety set), n (%)
| Fexuprazan 40 mg (n = 52) | Rabeprazole 20 mg (n = 54) | P value1 | |
| TEAE | 3 (5.77) | 2 (3.70) | 0.676 |
| 95%CI | 1.20-15.95 | 0.45-12.75 | |
| Serious TEAE | 0 (0.00) | 0 (0.00) | |
| Drug-related TEAE | 0 (0.00) | 2 (3.70) | 0.495 |
| 95%CI | - | 0.45-12.75 | |
| Serious drug-related TEAE | 0 (0.00) | 0 (0.00) |
- Citation: Lee DS, Lee SW, Kang SH, Moon HS, Sung JK, Kim SH, Lee DK, Kim KB, Kim SM, Cho YS, Kim JS. Comparing fexuprazan and rabeprazole for treating peptic ulcer: A multicenter, randomized controlled trial. World J Gastroenterol 2026; 32(25): 119434
- URL: https://www.wjgnet.com/1007-9327/full/v32/i25/119434.htm
- DOI: https://dx.doi.org/10.3748/wjg.119434